MARKET

AXSM

AXSM

Axsome Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.84
+1.10
+2.57%
Opening 09:40 07/07 EDT
OPEN
42.75
PREV CLOSE
42.74
HIGH
44.00
LOW
42.75
VOLUME
76.34K
TURNOVER
2.16M
52 WEEK HIGH
66.13
52 WEEK LOW
19.38
MARKET CAP
1.71B
P/E (TTM)
-11.7903
1D
5D
1M
3M
1Y
5Y
What Is The Ownership Structure Like For Axsome Therapeutics, Inc. (NASDAQ:AXSM)?
The big shareholder groups in Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) have power over the company. Institutions often...
Simply Wall St. · 3d ago
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA).  SVB Leerink says its view on Sunosi has not chang...
Benzinga · 06/29 19:22
Analyst Ratings for Axsome Therapeutics
Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:
Benzinga · 06/29 15:03
Axsome draws 36% hike for price target at Cantor on prospects for Sunosi
Cantor Fitgerald raised its price target on commercial-stage biopharma Axsome Therapeutics (NASDAQ:<a href="https://seekingalpha.com/symbol/AXSM?utm_medium=referral&utm_source=webull.com" title="Axsome Therapeut...
Seekingalpha · 06/29 13:24
Cowen Adjusts Axsome Therapeutics' Price Target to $130 from $120, Keeps Outperform Rating
MT Newswires · 06/29 11:31
Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual event today at 9:...
GlobeNewswire · 06/28 11:00
EVFM, DTIL and SRRK among mid-day movers
Gainers: Evofem Biosciences (EVFM) +172%. Acutus Medical (AFIB) +97%. NeuroSense (NRSN) +52%. Axsome (AXSM) +42%. Clene (CLNN) +35%. AeroClean (AERC) +28%. Femasys (FEMY) +30%. Scholar Rock Holding (SRRK) +22%. Precision
Seekingalpha · 06/27 16:34
Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical
Axsome Therapeutics Inc (NASDAQ: AXSM) shares rallied 40% on Monday morning after the company received some positive news from the U.S. Food and Drug Administration regarding its AXS-05 novel treatment for MDD (depression).
Benzinga · 06/27 14:45
More
No Data
Learn about the latest financial forecast of AXSM. Analyze the recent business situations of Axsome Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
42.86%Buy
7.14%Hold
7.14%Under-perform
0.00%Sell
Analyst Price Target
The average AXSM stock price target is 81.31 with a high estimate of 180.00 and a low estimate of 27.00.
High180.00
Average81.31
Low27.00
Current 44.25
EPS
Actual
Estimate
-0.98-0.73-0.49-0.24
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 247
Institutional Holdings: 24.47M
% Owned: 62.89%
Shares Outstanding: 38.91M
TypeInstitutionsShares
Increased
40
1.41M
New
33
1.38M
Decreased
62
1.78M
Sold Out
21
337.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.88%
Pharmaceuticals & Medical Research
+0.66%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Executive Vice President
Lori Englebert
Executive Vice President
Hunter Murdock
Senior Vice President
Amanda Jones
Lead Director/Independent Director
Roger Jeffs
Independent Director
Mark Coleman
Independent Director
Mark Saad
No Data
No Data
About AXSM
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral multi-mechanistic medicine for the acute treatment of migraine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-09 is an oral NMDA receptor antagonist with multimodal activity consisting of esbupropion and dextromethorphan for the treatment of CNS disorders. AXS-12, reboxetine, is an oral medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine is an oral medicine in development for the treatment of fibromyalgia.

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.